Biodesix Obtains US Patent for Protein Biomarker-Based VeriStrat Lung Cancer Test

A company official said that VeriStrat sales are growing at a double-digit pace and that Biodesix is also looking to apply the test to diseases beyond lung cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.